Asgard Therapeutics secures €30M Series A funding for its in vivo cell reprogramming platform for immuno-oncology.

Asgard Therapeutics secures €30M Series A funding, led by RV Invest and JJDC, to advance its 1st-in-class in vivo cell reprogramming platform for immuno-oncology. Lead program, AT-108, is an off-the-shelf intra-tumoral therapy driving personalized anti-cancer immune responses. The funding will expand the R&D team and broaden the in vivo reprogramming pipeline.